Struggling with weight despite dieting and exercise?
Wegovy® (semaglutide) is a prescription medication used for chronic weight management in adults with obesity or weight-related medical conditions.
At Sheen Clinic in Subang Jaya, Wegovy treatment is provided under medical supervision with structured monitoring, lifestyle guidance, and individualised dose adjustment.

Real patient after Weight loss injection treatment
Wegovy® contains semaglutide 2.4 mg, a GLP-1 receptor agonist approved for chronic weight management.
It works by:
Reducing appetite
Increasing satiety (feeling full)
Slowing gastric emptying
Helping regulate calorie intake
Wegovy is administered as a once-weekly subcutaneous injection.
Wegovy may be appropriate for:
Adults with BMI ≥30 kg/m² (obesity)
Adults with BMI ≥27 kg/m² with weight-related conditions such as:
Hypertension
Type 2 diabetes
Dyslipidaemia
Obstructive sleep apnoea
Eligibility is determined after medical assessment.
You may consider Wegovy if:
Diet and exercise alone have not resulted in sustainable weight loss
You experience persistent hunger or cravings
You have weight-related medical conditions
You need medically supervised weight management
Lifestyle programs alone have been insufficient
Wegovy is not intended for cosmetic weight loss in individuals with normal BMI.
Semaglutide mimics the hormone GLP-1 (glucagon-like peptide-1).
Mechanism of action:
Activates GLP-1 receptors in the brain
Reduces appetite signals
Increases satiety
Lowers caloric intake
Supports gradual, sustained weight reduction
Weight loss typically occurs progressively over several months.

Clinical trials have shown:
Significant percentage body weight reduction over 68 weeks
Greater weight loss compared to lifestyle intervention alone
Improvement in cardiometabolic risk factors
Individual results vary depending on:
Adherence
Lifestyle habits
Metabolic factors
Baseline weight
Weight management is a long-term strategy.
Wegovy is initiated gradually to minimise side effects.
Typical dose escalation:
0.25 mg weekly (starting dose)
Gradual increase every 4 weeks
Target maintenance dose: 2.4 mg weekly
Monitoring includes:
Weight tracking
Blood pressure
Metabolic parameters (if indicated)
Side effect assessment
Lifestyle guidance is provided alongside medication.

Most side effects are gastrointestinal and temporary:
Nausea
Vomiting
Diarrhoea
Constipation
Reduced appetite
These symptoms are usually more common during dose escalation.
Seek medical advice if experiencing:
Persistent severe abdominal pain
Signs of pancreatitis
Severe dehydration

Wegovy is not suitable for:
Pregnancy or breastfeeding
Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2 (MEN 2)
History of severe hypersensitivity to semaglutide
A full medical history is required before prescribing.
Appetite reduction may begin within weeks. Noticeable weight reduction typically develops over several months.
Clinical studies show average weight loss of approximately 10–15% of body weight over extended treatment periods, though results vary.
Yes. Wegovy works best when combined with dietary changes and physical activity.
Weight regain may occur if medication is discontinued without maintaining lifestyle changes.
Both contain semaglutide, but Wegovy is specifically approved at higher doses for chronic weight management.
Wegovy is a prescription-only medication and must be administered under medical supervision.
Safe treatment requires:
Proper patient selection
Gradual dose escalation
Monitoring for side effects
Ongoing follow-up
Unsupervised use increases risk of complications.
Patient Testimonial and experience
Picture show real patient google screenshoot where her weight reduce 10kg
Sheen Clinic is located in Subang Jaya and serves patients from:
USJ
Sunway
Puchong
Shah Alam
Kuala Lumpur
Regular follow-up is important for safe, effective weight management.
Treatment: Wegovy (semaglutide 2.4 mg)
Indication: Chronic weight management in adults with obesity or overweight with comorbidities
Mechanism: GLP-1 receptor agonist reducing appetite and caloric intake
Administration: Once-weekly subcutaneous injection
Dose escalation: Gradual increase to 2.4 mg
Common side effects: Nausea, vomiting, gastrointestinal symptoms
Monitoring: Medical supervision required
Patients interested in Wegovy treatment in Subang Jaya may schedule a medical consultation for eligibility assessment and personalised weight management planning.
If you are searching for Sunspot removal treatment in Subang Jaya, schedule a consultation to determine whether this treatment is suitable for your skin condition.
Contact Us: +60122828493
Website: Sheen Clinic
Locations: Subang Jaya & Kuala Lumpur, Malaysia
Malaysia